Please login to the form below

Not currently logged in
Email:
Password:

GSK to cut 3,000 jobs

GlaxoSmithKline is to announce more than 3,000 job cuts at its European and US operations as a result of a shift in focus to emerging markets

It is reported that GlaxoSmithKline is to announce more than 3,000 job cuts at its European and US operations as a result of a shift in focus from stagnant Western markets to China in particular, and emerging markets in Asia and Latin America.

GSK aims to reduce £1.7bn in annual costs by the end of next year and re-focus efforts on research and development. Demand for the company's Pandremix vaccine against H1N1 has been lower than anticipated and sales of GSK's H1N1 drug Relenza have also fallen short.

Analysts have said that the group is too reliant on aging patents – the company has been hit most recently by generic versions of its herpes treatment Valtrex after expiry of its US patent.

1st February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

The_Pharma_Wars_Series.png
The Pharma Wars Series
The future galaxy is complex. Where markets are more competitive and customers more segmented, you’ve got to be smarter. But not only smarter, the Jedi today needs to be everywhere...
What pharma marketers can learn from growth hacking?
Growth hackers instinctively blend technical skills with creative thinking...
Medicines for Europe
The sound of silence puts the squeeze on generics and biosimilars
Medicines for Europe vows to get governments talking to realise potential...

Infographics